Status: Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
Participants needed: 150
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Oct 8, 2026Locations: 59
Eligibility criteria
Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional... [+4]
Evidence of lymph node (N2-N3) or metastatic (M1) disease [+5]